Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
Sponsor: BRIM Biotechnology Inc.
Summary
To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)
Official title: A Phase 2, Multicenter, Randomized, Open-Labeled, Artificial Tear-Controlled, 6-Week Clinical Study to Assess the Dose Regimen, Safety and Efficacy of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
99
Start Date
2025-12
Completion Date
2027-03
Last Updated
2025-10-20
Healthy Volunteers
No
Interventions
BRM421 Ophthalmic Solution, 0.03%
A topical drop of 0.03% BRM421 ophthalmic solution.
Artificial Tear
A topical drop of Artificial Tear.
BRM421 Ophthalmic Solution, 0.06%
A topical drop of 0.06% BRM421 ophthalmic solution.
Locations (1)
New Taipei Municipal TuCheng Hospital
New Taipei City, Taiwan